Offloading Notebook PCs to End-Users


By Salvatore Salamone Bio-IT World

Most people load software onto their company notebook computers – even if they are not supposed to.

Personally, I’ve got Google Desktop, Palm Pilot software, the drivers for my digital camera, and a wireless adapter card, open-source programs Thunderbird and Audacity, and licensed copies (which I purchased) of Microsoft Front Page and Adobe Acrobat loaded onto my Bio-IT World notebook computer.

Many life scientists and most people I encounter have a similar mix of personal software installed on their company notebooks. It’s a fact of life these days.

People often work nights and weekends and feel as though they own the computer. So the general feeling is, Why not customize it to the extent allowed by their IT departments?

Such behavior and feelings are the seeds behind a nascent, yet soon-to-be-growing, trend: employee ownership of notebook computers.

The IT consultancy Gartner predicts that by 2008, 10 percent of companies will require that employees purchase their own notebook computers. Gartner believes the shift will likely be encouraged by offering employees some form of notebook allowances similar to the way many companies today offer car mileage allowances to sales reps and others who need a car to do their job.

From an IT perspective, the shift to employee-owned notebooks carries a mixed bag of pros and cons. “Transferring notebook ownership to employees does not eliminate the cost of PCs, but shifts it to employee benefits and indirect user operational costs,” said Leslie Fiering, research vice president at Gartner. She noted that the payback to a company is in removing PC assets from company books.

Naturally, transferring ownership to employees carries risks especially if a notebook contains corporate data that might cause liability or fiduciary problems if that data is released. Similarly, lab data on a home notebook, if not properly safeguarded, might present intellectual property protection problems and possibly regulatory compliance issues.

Obviously, there will have to be adequate security and policies in place to deal with these problems. But the question is: Who will be responsible for ensuring that a notebook is secured?

It is likely that IT will retain responsibility for maintaining security since most people are not very vigilant about securing their home computers.

A recent survey by America Online and the National Cyber Security Alliance found that 81 percent of home PC users lacked at least one of the three key security features (antivirus software, a firewall, and spyware protection) deemed necessary to protect a computer today. And many people who had these secure software packages installed did not update them frequently enough to protect their computers.

To address such shortcomings, organizations will have to turn to tools that automatically update antivirus and spyware detection software. And there will also be a need to check a personal firewall’s properties to make sure it has not been readjusted by a home user in such a way as to compromise corporate standards for safety.

IT departments already do most of these tasks on a regular basis with corporate-owned notebooks. If user-owned notebooks become the norm, the biggest difference will be the need for policies that give IT the authority to require that notebooks meet specific security standards before they can connect to the corporate network.

What do you think of user-owned notebooks? Would this reduce or add to your computer support workload? Do you anticipate any particular problems that might arise when using such computers in a regulated environment? How might you address these problems? Drop me a note with your thoughts on the subject. I can be reached at Salvatore_Salamone@bio-itworld.com

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.